THIS PRESS RELEASE MAY NOT BE DISCLOSED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR TO AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SWITZERLAND,. | May 31, 2023
Prostatype Genomics AB announces today the final outcome of the share issue with preferential rights for the Company s shareholders whose subscription period ended on 11 May 2023. The subscription. | May 16, 2023
/PRNewswire/ Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics..
On March 30, 2023, the exercise period for Prostatype Genomics AB s warrants of series TO 2 ended. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to SEK 7,603.80.
During. | April 4, 2023
Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company s wholly owned subsidiary, Prostatype Genomics Inc. Steven s task will be to establish and launch Prostatype®, the company s genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately.